Most recently, Superluminal Medicines raised $65.5M in its Series B (Sep 2026).
- ·The post-money valuation on its round
- ·The complete investor list: 12 names
- ·Watch Superluminal Medicines: the Monday email on marks, rounds and moves
Superluminal Medicines round by round
4 roundsHow much has Superluminal Medicines raised?
Superluminal Medicines has raised $158 million across 4 recorded rounds since 2023. The largest was a $65.5 million Series B in Sep 2026. 1 of the rounds disclosed a post-money valuation.
Superluminal Medicines has filed 3 Form Ds with the SEC since 2023, most recently in Aug 2025 ($5 million sold to 1 investor).
Superluminal Medicines investors
12 investors are on record for Superluminal Medicines, including Insight Partners (New York), Gaingels, RA Capital Management and Evolution VC Partners. By type, the record holds 5 venture capital firms, 1 hedge fund and 1 asset manager. The Series B in Sep 2026 drew 10 investors.
12 investors have backed Superluminal Medicines — start your target list with the firms already writing checks in drug discovery.
Frequently asked about Superluminal Medicines
- How much has Superluminal Medicines raised?
- Superluminal Medicines has raised $157.7M in total across 4 recorded funding rounds.
- When was Superluminal Medicines's last funding round?
- Superluminal Medicines's most recent recorded round was Series B in Sep 2026, raising $65.5M.